ZEAL News and Press, Zealand Pharma A/S From 11/07/23

Press release – No. 15 / 2023 Zealand Pharma to participate in the Jefferies London Healthcare Conference in November 2023 Copenhagen, Denmark, November 7, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery a...

Press Release – No. 14 / 2023 Zealand Pharma conference call on November 9 at 2pm CET (8am ET) to present third quarter 2023 results Copenhagen, Denmark, November 3, 2023 – a Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the disc...

Press release – No. 13 / 2023 Zealand Pharma presents data for amylin analog ZP8396 at ObesityWeek Copenhagen, Denmark, October 17, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) (CVR-no. 20045078) a biotechnology company focused on the discov...

Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease Press release – No. 12 / 2023 SYNCHRONIZE-1 and SYNCHRONIZE-2 are global Phase III studies of survodutide (BI...

Press release – No. 11 / 2023 SAVE THE DATE: Zealand Pharma to host Obesity R&D Event in London on December 5, 2023 Copenhagen, Denmark, September 8, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and...

Press release – No. 10 / 2023 Zealand Pharma to participate in upcoming healthcare conferences in September 2023 Copenhagen, Denmark, September 7, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and develo...

Company announcement – No. 31 / 2023 Zealand Pharma announces designation of priority review by the US FDA for dasiglucagon in congenital hyperinsulinism US FDA has granted priority review designation to dasiglucagon for the prevention and treatment of hypoglycemia in pedia...

Company announcement - No. 28 / 2023 Zealand Pharma Announces Financial Results for the First Half of 2023 Strong progress across R&D pipeline and significant strengthening of the balance sheet Boehringer Ingelheim to move into Phase 3 trials with GCGR/GLP-1R dual agonis...

Press Release – No. 9 / 2023 Zealand Pharma Hosts Conference Call on August 17 at 2pm CET (8am ET) to Present First Half 2023 Results Copenhagen, Denmark, August 14, 2023 – a Zealand Pharma A/S (CVR-no. 20045078), a biotechnology company focused on the...

Company announcement – No. 27 / 2023 Zealand Pharma announces positive results from Part 1 of multiple ascending dose trial with amylin analog ZP8396 Doses of 0.6 and 1.2 mg ZP8396 administered once-weekly for six weeks led to 5.3% and 5.1% mean weight loss as compared to 2.6...